

DIRECTOR OF NEUROPATHOLOGY

The University of Toronto and Toronto General Hospital seek a neuropathologist to coordinate research, clinical service and training programs in neuropathology. The position, available July 1, 1982, carries the academic rank of professor.

The successful candidate will be expected to direct undergraduate, graduate and residency teaching programs, participate in diagnostic neuropathology service, and to develop an independent research program in neuropathology.

Candidates must be certified in neuropathology and be eligible for Ontario licensure. They should have demonstrated excellence in teaching, research, and diagnostic neuropathology and should possess recognized administrative ability.

Applications with curriculum vitae and the names of three references should be sent, before February 15th, to:



Dr. Emmanuel Farber
Professor and Chairman
Department of Pathology
University of Toronto
100 College Street
Toronto, Ontario
M5G 1L5, Canada.

NEUROPHYSIOLOGIST and NEUROENDOCRINOLOGIST


The Department of Physiology of the University of Manitoba, Winnipeg, Canada, is seeking a neurobiologist at the assistant professor level, Ph.D. or M.D. and post-doctoral experience are required. Preference will be given to individuals with a research interest in 1) neurobiology of movement, 2) developmental neurobiology, 3) peptide neurobiology, and 4) neuroendocrinology. Both men and women are encouraged to apply. In accordance with Canadian Employment and Immigration policy, consideration in the first instance will be given only to Canadian citizens and permanent residents. Send curriculum vitae, a description of current and prospective research programs, and three letters of reference to:

Larry M. Jordan, Ph.D.,
Department of Physiology,
The University of Manitoba,
Faculty of Medicine, 770 Bannatyne Avenue,
WINNIPEG, CANADA, R3E 0W3,
by the 15th of March, 1982.

NEUROPATHOLOGY

Research Associate required for laboratory investigations of senile dementia Alzheimer type in an established clinicopathological, multi-disciplinary project. Successful applicant must hold M.D. degree, and preference will be given to Canadian citizens or landed immigrants. Postgraduate trainees (residents) in Neurology, Anatomical Pathology, Neuropathology or Psychiatry may acquire credit during this collaboration towards Royal College fellowship requirements. Excellent opportunity for research-oriented physician to gain experience in neurobiological techniques, including neuroanatomical, neuropathological (including morphometric), biochemical, neuropharmacological, and peptide analyses. Close liaison encouraged with both renowned neurological clinicians and basic neuroscientists. Salary commensurate with experience. Position available immediately; appointment possible for periods of from 1 to 3 years. Send curriculum vitae and names of 3 references to:

Professor M.J. Ball,
Department of Pathology,
University of Western Ontario,
LONDON, Ontario N6A 5C1
CANADA.



New Sandomigran[®] DS

Specific, Double Strength headache prophylaxis.

PRESCRIBING INFORMATION

SANDOMIGRAN (pizotyline) SANDOMIGRAN D.S.

Dosage - The average maintenance dosage is 0.5 mg 11 d. A progressive dosage is recommended until the fifth day of therapy. The dosage range is 1 to 6 mg per day.

Since vascular headache is a paroxysmal but basically chronic disorder, treatment must extend over an adequate period of time in order to obtain maximal benefit. While some patients have responded rather quickly, most investigators agree that a four-week trial period should be instituted to determine the true efficacy of pizotyline in specific cases. The periodic nature of the disorder will have to be considered in determining when and for how long therapy should be maintained. Since some investigators have observed a change in headache pattern after several months of therapy, a drug-free interval is advisable to reassess the necessity of continuing treatment. The dosage should be reduced gradually during the last two weeks of each treatment course to avoid a headache rebound.

Composition - Each ivory, sugar-coated tablet contains 0.5 mg of pizotyline as the hydrogen malate. Each single scored white tablet contains 1 mg of pizotyline as the hydrogen malate.

Contraindications - Anticholinergic agents, including pizotyline, are contraindicated in patients taking monoamine oxidase inhibitors and in patients with pyloroduodenal obstruction and stenosing pyloric ulcer. Pizotyline is also contraindicated for patients who have a known sensitivity to the drug. Until further studies are completed, the drug is not recommended for children under the age of twelve.

Warnings and precautions - Since drowsiness may occur with pizotyline, sensitive patients should be cautioned against activities requiring rapid and precise response (i.e. driving an automobile or operating dangerous machinery) until their response to the drug has been determined. Since the effects of antihistamines can potentiate those of other drugs affecting the central nervous system, patients should be cautioned against drinking alcoholic beverages or taking hypnotics, sedatives, psychotherapeutic agents or other drugs with CNS depressant effects during pizotyline therapy. Administer pizotyline with caution to patients with narrow angle glaucoma or with urinary retention (e.g. prostatic hypertrophy).

Since it is desirable to keep drug administration to a minimum during pregnancy, pizotyline should be given only when the benefits derived from treatment exceed the possible risks to mother and fetus.

Some patients developed tolerance to pizotyline with prolonged use of the drug. An increase in dosage may overcome this tolerance.

After prolonged use, hepatotoxic effects might occur and patients should be advised to report for adequate laboratory evaluation.

Patients with diabetes, cardiovascular disease and known or suspected impaired renal or hepatic function should be given pizotyline with caution and appropriate laboratory tests should be done at regular intervals.

Lens opacities occurred in two cases but did not appear to be drug related. However, it is recommended that any impairment in vision be reported to the attending physician for further investigation.

Side effects - Increased appetite, weight gain, and drowsiness are the most frequent side effects. An appropriate diet should be recommended by the physician for patients benefiting from the drug but gaining excessive weight. A gradual increase in the dosage of pizotyline is recommended to minimize or reduce the incidence of drowsiness. The following adverse effects have been observed less frequently in relation to the aforementioned reactions: fatigue, nausea, dizziness, headache, confusion, edema, hypotension, depression, weakness, epigastric distress, dry mouth, nervousness, impotence and muscle pain.

Supply - 0.5 mg tablets in bottles of 100 and 500. 1 mg scored tablets in bottles of 100.

Complete prescribing information available on request.

PAAB

PMAC

SANDOZ[®]



Sandoz (Canada) Limited, Dorval, Quebec

Prolopa[®] Roche[®]

Rx Summary

Indications

Treatment of Parkinson's syndrome with the exception of drug-induced parkinsonism.

Contraindications

Known hypersensitivity to levodopa and/or benserazide. In patients in whom sympathomimetic amines are contraindicated; in conjunction with monoamine oxidase inhibitors or within two weeks of their withdrawal. Clinical or laboratory evidence of uncompensated cardiovascular, endocrine, renal, hepatic, hematologic or pulmonary disease; narrow-angle glaucoma (may be used in wide-angle glaucoma provided intraocular pressure remains under control). History of melanoma or suspicious undiagnosed skin lesions.

Warnings

Discontinue levodopa therapy at least 12 hours before initiating 'Prolopa' therapy. Increase dosage of 'Prolopa' 100-25 gradually to avoid inducing CNS side effects (abnormal movements). Observe patients for signs of depression with suicidal tendencies or other serious behavioural changes. Caution in patients with history of psychotic disorders or those receiving reserpine, phenothiazines or tricyclic antidepressants. Administer with care to patients with history of myocardial infarction or who have atrial, nodal or ventricular arrhythmias.

Safety in patients under 18 years has not been established. In women who are or may become pregnant benefits should be weighed against possible hazards to mother and fetus. Should not be given to nursing mothers.

Precautions

Caution in patients with history of convulsive disorders. Upper gastrointestinal hemorrhage possible in patients with history of peptic ulcer.

Normal activity should be resumed gradually to avoid risk of injury.

Administer with caution to patients on antihypertensive medication; discontinue 12 hours before anesthesia. Monitor intraocular pressure in patients with chronic wide-angle glaucoma.

Adverse reactions

Most common are abnormal involuntary movements, usually dose dependent, and may disappear or become tolerable after dosage reduction.

Most serious after prolonged therapy are periodic oscillations in performance (end of dose akinesia, on-off phenomenon and akinesia paradoxa).

Nausea, vomiting, arrhythmias and orthostatic hypotension occur less frequently than with levodopa alone. Psychiatric disturbances, including mild elation, depression, anxiety, agitation, aggression, hallucinations and delusions have been encountered. Consult monograph for complete list of reported adverse effects.

Dosage

Recommended initial dose is one capsule 'Prolopa' 100-25 once or twice daily, increased carefully by one capsule every third or fourth day until an optimum therapeutic effect is obtained without dyskinesias. At upper limits of dosage increments should be made slowly at 2 to 4-week intervals.

Optimal dosage for most patients is 4 to 8 capsules of 'Prolopa' 100-25 daily (400-800 mg levodopa) divided into 4 to 6 doses. Most patients require no more than 6 capsules 'Prolopa' 100-25 (600 mg levodopa) per day. 'Prolopa' 200-50 capsules are intended only for maintenance therapy once the optimal dosage has been determined using 'Prolopa' 100-25 capsules. No patients should receive more than 5 to 6 capsules 'Prolopa' 200-50 daily (1000 to 1200 mg levodopa) during the first year of treatment.

For patients previously treated with levodopa discontinue for 12 hours and initiate with 'Prolopa' 100-25 to provide approximately 15% of previous levodopa dosage. The initial daily dose, however, should not exceed 6 capsules 'Prolopa' 100-25 divided into 4 to 6 doses.

Supply

Blue, flesh-coloured capsules imprinted ROCHE C and PROLOPA 100-25 (black ink) alternating between body and cap each containing 100 mg levodopa and 25 mg benserazide.

Blue, caramel-coloured capsules imprinted ROCHE C and PROLOPA 200-50 (black ink) alternating between body and cap, each containing 200 mg levodopa and 50 mg benserazide. Bottles of 100. Product monograph available on request.

® Reg. Trade Mark

'Prolopa' is listed in provincial formularies.

PAAB
CCPP



Hoffmann-La Roche Limited
Vaudreuil, Québec J7V 6B3

(xvii)

this publication is available in microform



Please send me additional information.

University Microfilms International

300 North Zeeb Road
Dept. P.R.
Ann Arbor, MI 48106
U.S.A.

18 Bedford Row
Dept. P.R.
London, WC1R 4EJ
England

Name _____
Institution _____
Street _____
City _____
State _____ Zip _____

How do you spell truth in advertising?

PAAB
CCPP

This logo appearing on pharmaceutical advertisements in professional journals means that the advertisements have been reviewed—and cleared for publishing—by the Pharmaceutical Advertising Advisory Board/Conseil Consultatif de Publicité Pharmaceutique.

This unique screening system for pharmaceutical advertising is the first of its kind in North America. The Board of Directors is composed of individuals representing the following organizations: Association des fabricants du Québec de Produits Pharmaceutiques - Association des médecins de langue française du Canada - Association of Medical Media - Canadian Advertising Advisory Board - Canadian Drug Manufacturers - Canadian Medical Association - Canadian Pharmaceutical Association - Consumers' Association of Canada - Pharmaceutical Manufacturers Association of Canada.

The Health Protection Branch of Health and Welfare Canada acts as advisor and resource body to the board.

The program ensures the accuracy of pharmaceutical advertising to the health professions, so that it may continue to serve the ultimate best interest of the patient.

INDEX TO ADVERTISEMENTS

- Beckman EEG — (xii)
- Frosst, Entrophen — (x) and (xi)
- Geigy, Tegretol — outside back cover and Lioresal — (viii)
- Grass Instruments, Polysomnographic Recording (xvi)
- Heerbrugg Microscopes — (xiii)
- Hoffman-LaRoche, Rivotril (ii), Prolopa (xx)
- Parke Davis, Dilantin, Zarontin — (i) and (xviii)
- Sandoz Pharmaceuticals, Fiorinal — (vii) and (xviii) New Sandomigran DS — (iii) and (xvii)
- Unimed Canada, Serc - inside front cover

(ASA U.S.P. 330 mg, ⊕ Sandoptal® (butalbital) 50 mg, caffeine U.S.P. 40 mg.)

Contraindications
Porphyria, hypersensitivity to any of the components.

Precautions
Due to the presence of butalbital Fiorinal may be habit-forming. Excessive or prolonged use should be avoided.

Activities requiring mental alertness should not be undertaken until the patient's response and sensitivity to the medication have been established.

Fiorinal should be used with caution in the presence of peptic ulcer.

During pregnancy and lactation, Fiorinal should be taken only upon medical advice.

Adverse reactions
Drowsiness, dizziness, nausea, constipation and skin rash may occur in rare instances.

Dosage
Adults, 2 tablets or capsules at once, followed if necessary, by 1 tablet or capsule every 3 to 4 hours, or as directed by the physician. Maximum daily dose: 6 tablets or capsules.

Children, 1 to 3 tablets or capsules a day, according to age.

Supply
Capsules or Tablets, bottles of 100 and 500.

1. Federal Register, Vol. 42, No. 220: 59115. Tuesday, November 15, 1977.

Complete prescribing information available on request.

Sandoz (Canada) Limited
P.O. Box 385, Dorval, Quebec H9R 4P5



BRIEF PRESCRIBING INFORMATION
DILANTIN[®]
Extended Phenytoin Sodium Capsules, U.S.P. 100 mg
ANTICONVULSANT

INDICATIONS
Dilantin is indicated for the control of generalized tonic-clonic (grand mal) seizures and complex partial (psychomotor) seizures.

CONTRAINDICATIONS
Dilantin is contraindicated in those patients with a history of hypersensitivity to hydantoin products.

WARNINGS
Abrupt withdrawal of phenytoin in epileptic patients may precipitate status epilepticus. Phenytoin is not indicated in seizures due to hypoglycemia or other causes which may be immediately identified and corrected. Phenytoin metabolism may be significantly altered by the concomitant use of other drugs such as:

A Barbiturates may enhance the rate of metabolism of phenytoin. This effect, however, is variable and unpredictable. It has been reported that in some patients the concomitant administration of carbamazepine resulted in an increased rate of phenytoin metabolism.

B Coumarin anticoagulants, disulfiram, phenylbutazone, and sulfaphenazole may inhibit the metabolism of phenytoin, resulting in increased serum levels of the drug. This may lead to an increased incidence of nystagmus, ataxia, or other toxic signs.

C Isoniazid inhibits the metabolism of phenytoin so that with combined therapy, patients who are slow acetylators may suffer from

phenytoin intoxication.
D Tricyclic antidepressants in high doses may precipitate seizures, and the dosage of phenytoin may have to be adjusted accordingly.

Usage in Pregnancy: The effects of Dilantin in human pregnancy and nursing infants are unknown.

The prescribing physician will have to determine the risk/benefit in treating or counselling epileptic women of childbearing potential.

PRECAUTIONS
The liver is the chief site of biotransformation of phenytoin, patients with impaired liver function may show early signs of toxicity. Elderly patients or those who are gravely ill may show early signs of toxicity.

A small percentage of individuals who have been treated with phenytoin have been shown to metabolize the drug slowly. Slow metabolism may be due to limited enzyme availability and lack of induction; it appears to be genetically determined.

Phenytoin has been associated with reversible lymph node hyperplasia. If lymph node enlargement occurs in patients on phenytoin, every effort should be made to substitute another anticonvulsant drug or drug combination.

Drugs that control generalized tonic-clonic (grand mal) seizures are not effective for absence (petit mal) seizures. Therefore, if both conditions are present, combined drug therapy is needed.

Hyperglycemia, resulting from the drug's inhibitory effect on insulin release, has been reported. Phenytoin may also raise the blood sugar level in persons already suffering from hyperglycemia.

ADVERSE REACTIONS
Central Nervous System: The most common manifestations encountered with phenytoin

therapy include nystagmus, ataxia, slurred speech, and mental confusion. Dizziness, insomnia, transient nervousness, motor twitchings, and headache have also been observed. These side effects may disappear with continuing therapy at a reduced dosage level.

Gastrointestinal System: Phenytoin may cause nausea, vomiting, and constipation. Administration of the drug with or immediately after meals may help prevent gastrointestinal discomfort.

Integumentary System: Dermatological manifestations sometimes accompanied by fever have included scarlatiniform or morbilliform rashes.

Hemopoietic System: Hemopoietic complications, some fatal, have occasionally been reported in association with administration of phenytoin. These have included thrombocytopenia, leukopenia, granulocytopenia, agranulocytosis, and pancytopenia.

Other: Gingival hyperplasia occurs frequently; this incidence may be reduced by good oral hygiene including gum massage, frequent brushing and appropriate dental care. Polyarthropathy and hirsutism occur occasionally. Hyperglycemia has been reported. Toxic hepatitis, liver damage, and periarteritis nodosa may occur and can be fatal.

MANAGEMENT OF OVERDOSAGE
The mean lethal dose in adults is estimated to be 2 to 5 grams. The cardinal initial symptoms are hystagmus, ataxia and dysarthria. The patient then becomes comatose, the pupils are unresponsive and hypotension occurs. Death is due to respiratory depression and apnea. Treatment is non-specific since there is no known antidote. First, the stomach should be emptied. If the gag reflex is absent, the airway should be supported. Oxygen, vasopressors and assisted ventilation may be necessary for central nervous system, respiratory and

cardiovascular depression. Finally, hemodialysis can be considered since phenytoin is not completely bound to plasma proteins.

DOSAGE AND ADMINISTRATION
Dosage should be individualized to provide maximum benefit. In some cases, serum blood level determinations may be necessary for optimal dosage adjustments—the clinically effective serum level is usually 10–20 mcg/mL.

Adult Dose: Patients who have received no previous treatment may be started on one 100 mg Dilantin Capsule three times daily, and the dose then adjusted to suit individual requirements.

Pediatric Dose: Initially, 5 mg/kg/day in two or three equally divided doses, with subsequent dosage individualized to a maximum of 300 mg daily. A recommended daily maintenance dosage is usually 4 to 8 mg/kg. Children over 6 years old may require the minimum adult dose (300 mg/day). Pediatric dosage forms available include a 30 mg Capsule, a 50 mg palatably flavoured Infatab, or an oral suspension form containing 30 mg of Dilantin in each 5 mL.

Alternative Dose: Once-a-day dosage for adults with 300 mg of Dilantin may be considered if seizure control is established with divided doses of three 100 mg Capsules daily.

HOW SUPPLIED
Dilantin 100 mg Capsules; in bottles of 100 & 1000.

Complete prescribing information available upon request.

PARKE-DAVIS

Parke-Davis Canada Inc., Scarborough, Ontario
*Reg. T.M. Parke-Davis & Company
Parke-Davis Canada Inc., auth. user



Brief Prescribing Information
Tegretol® 200 mg carbamazepine

Indications and Clinical Use

A. Trigeminal Neuralgia:

Tegretol is indicated for the symptomatic relief of pain of trigeminal neuralgia only during periods of exacerbation of true or primary trigeminal neuralgia (tic douleureux). It should not be used preventively during periods of remission. In some patients, Tegretol has relieved glossopharyngeal neuralgia. For patients who fail to respond to Tegretol, or who are sensitive to the drug, recourse to other accepted measures must be considered.

Tegretol is not a simple analgesic and should not be used to relieve trivial facial pains or headaches.

B. Tegretol has been found useful:

- 1) in the management of psychomotor (temporal lobe) epilepsy and,
- 2) as an adjunct, in some patients with secondary or partial epilepsy with complex symptomatology or secondarily generalized seizures, when administered in combination with other antiepileptic medication.
- 3) as an alternative medication in patients with generalized tonic-clonic seizures who are experiencing marked side effects or fail to respond to other anticonvulsant drugs.

Tegretol is essentially ineffective in controlling petit mal, minor motor, myoclonic and predominantly unilateral seizures, and does not prevent the generalization of epileptic discharge.

Contraindications

Tegretol should not be administered to patients with a history of hepatic disease or serious blood disorder. Tegretol should not be administered immediately before, in conjunction with, or immediately after a monoamine oxidase inhibitor. When it seems desirable to administer Tegretol to a patient who has been receiving a MAO inhibitor, there should be as long a drug-free interval as the clinical condition allows, but in no case should this be less than 14 days. Then the dosage of Tegretol should be low initially, and increased very gradually.

Tegretol should not be administered to patients presenting atrioventricular heart block.

Safe use in pregnancy has not been established. Therefore, Tegretol should not be administered during the first three months of pregnancy. Tegretol should not be given to women of childbearing potential unless, in the opinion of the physician, the expected benefits to the patient outweigh the possible risk to the foetus (See Reproductive Studies). Because of demonstrated toxicity in nursing animals, Tegretol should not be administered to nursing mothers.

Because of the similarity of chemical structure, Tegretol should not be administered to patients with known hypersensitivity to any of the tricyclic compounds, such as amitriptyline, trimipramine, imipramine, or their analogues or metabolites.

Warnings

Although reported infrequently, serious adverse effects have been observed during the use of Tegretol. Agranulocytosis and aplastic anemia have occurred in a few instances with a fatal outcome. Leucopenia, thrombocytopenia and hepatocellular and cholestatic jaundice have also been reported. It is, therefore, important that Tegretol should be used carefully and close clinical and frequent laboratory supervision should be maintained throughout treatment in order to detect as early as possible signs and symptoms of a possible blood dyscrasia.

Long-term toxicity studies in rats indicated a potential carcinogenic risk. Therefore, the possible risk of drug use must be weighed against the potential benefits before prescribing carbamazepine to individual patients.

Precautions

Monitoring of Haematological and Other Adverse Reactions: Complete blood studies, including platelet counts, and evaluation of hepatic and renal function and urinalysis should be carried out before treatment is instituted. Careful clinical and laboratory supervision should be maintained throughout treatment, including frequent performance of complete blood counts, in order to detect any early signs or symptoms of blood dyscrasia. Should any signs or symptoms or abnormal laboratory findings suggestive of blood dyscrasia or liver disorder occur, Tegretol should be immediately discontinued until the case is carefully reassessed.

Urinary Retention and Increased Intraocular Pressure: Because of its anticholinergic action, Tegretol should be given cautiously, if at all, to patients with increased intraocular pressure or urinary retention. Such patients should be followed closely while taking the drug.

Occurrence of Behavioural Disorders: Because it is closely related to the other tricyclic drugs, there is some possibility that Tegretol might activate a latent psychosis, or, in elderly patients, produce agitation or confusion, especially when combined with other drugs. Caution should also be exercised in alcoholics.

Use in Patients with Cardiovascular Disorders: Tegretol should be used cautiously in patients with a history of coronary artery disease, organic heart disease, or congestive failure. If a defective conductive system is suspected, an E.K.G. should be performed before administering Tegretol, in order to exclude patients with atrioventricular block.

Use in Patients taking Oral Contraceptives: In women under treatment with Tegretol, the reliability of oral contraceptives may be adversely affected; such patients should accordingly be advised to use some alternative, non-hormonal method of contraception.

Driving and operating Hazardous Machinery: Because dizziness and drowsiness are possible side effects of Tegretol, patients should be warned about the possible hazards of operating machinery or driving automobiles.

Adverse Reactions

The reactions which have been most frequently reported with Tegretol are drowsiness, unsteadiness on the feet, vertigo, dizziness, gastrointestinal disturbances, and nausea. These reactions usually occur only

during the initial phase of therapy. They have rarely necessitated discontinuing Tegretol therapy, and can be minimized by initiating treatment at a low dosage. The more serious adverse reactions observed are the haematologic, hepatic, cardiovascular and dermatologic reactions, which require discontinuation of therapy.

The following adverse reactions have been reported:
Haematological reactions: Transitory leucopenia, eosinophilia, leucocytosis, thrombocytopenic purpura, agranulocytosis, macrocytic anemia and aplastic anemia. In a few instances, deaths have occurred.

Hepatic disturbances: During the long-term administration of Tegretol, abnormalities in liver function tests and cholestatic or hepatocellular jaundice have been observed.

Dermatological reactions: The following reactions occurred during treatment with Tegretol: skin sensitivity reactions and rashes, erythematous rashes, pruritic eruptions, urticaria, photosensitivity, pigmentary changes, neurodermatitis and in rare cases Stevens-Johnson syndrome, exfoliative dermatitis, alopecia, diaphoresis, erythema multiforme, erythema nodosum, and aggravation of disseminated lupus erythematosus.

Neurological reactions: The reactions reported as occurring during treatment with Tegretol include vertigo, somnolence, disturbances of coordination, confusion, headache, fatigue, blurred vision, transient diplopia and oculomotor disturbances, speech disturbances, abnormal involuntary movements and increase in motor seizures. In addition, peripheral neuritis and paresthesia, depression with agitation, talkativeness, nystagmus, and tinnitus have been reported but only very rarely. There have been some reports of paralysis and other symptoms of cerebral arterial insufficiency but no conclusive relationship to the administration of Tegretol could be established.

Cardiovascular systems: Recurrence of thrombophlebitis in patients with a prior history of thrombophlebitis, congestive heart failure, aggravation of hypertension, Stokes-Adams in patients with AV block, hypotension, syncope and collapse, edema, aggravation of coronary artery disease. Some of these complications (including myocardial infarction and arrhythmia) have been associated with other tricyclic compounds.

Genitourinary reactions: Urinary frequency, acute urinary retention, oliguria with elevated blood pressure, and impotence. Elevation of BUN, albuminuria and glycosuria also have been observed.

Digestive tract: Disturbances associated with Tegretol therapy have included nausea, vomiting, gastric or abdominal discomfort, diarrhoea, anorexia and dryness of the mouth and throat, glossitis and stomatitis.

Eyes: There is no conclusive evidence that Tegretol produces pathological changes in the cornea, lens or retina. However, it should be recognized that many phenothiazines and related drugs have been shown to cause eye changes. By analogy, periodic eye examinations, including slitlamp funduscopy and tonometry, are recommended.

Other reactions reported during treatment with Tegretol include fever and chills, lymphadenopathy, aching joints and muscles, leg cramps and conjunctivitis.

Dosage and Administration

Use in Epilepsy (see Indications): A low initial daily dosage with a gradual increase in dosage is advised. Dosage should be adjusted to the needs of the individual patient.

Adults and Children over 12 years of age: Initially, 100 to 200 mg once or twice a day depending on the severity of the case and previous therapeutic history. The initial dosage is progressively increased, until the best response is obtained, up to 600 mg daily. The usual optimal dosage is 600 mg daily, but occasionally dosages up to 800 to 1000 mg have been used for short periods. As soon as disappearance of seizures has been obtained and maintained, dosage should be reduced very gradually until a minimum effective dose is reached.

Use in trigeminal neuralgia: The initial daily dosage should be small: 200 mg, taken in two doses of 100 mg each is recommended. The total daily dosage can be increased by 200 mg per day until relief of pain is obtained. This is usually achieved at a dosage between 200 and 800 mg daily, but occasionally up to 1200 mg per day may be necessary. As soon as relief of pain has been obtained and maintained, progressive reduction in dosage should be attempted until a minimum effective dosage is reached. Because trigeminal neuralgia is characterized by periods of remission, attempts should be made to reduce or discontinue the use of Tegretol at intervals of not more than 3 months, depending upon the individual clinical course.

Prophylactic use of the drug in trigeminal neuralgia is not recommended. Tegretol should be taken in two or three divided doses daily, with meals whenever possible.

Dosage Forms

Tegretol is available as a 200 mg white, round, flat, bevelled-edged, double-scored tablet, imprinted with the GEIGY monogram.

Availability

Bottles of 50 and 500 tablets. Protect from heat and humidity.

Full information available on request.


See outside back cover.



Geigy
Dorval, Qué. H9S 1B1

New dosage flexibility
Prolopa 50-12.5 capsules

the
4:1
ratio



preferred by Parkinson patients




In Parkinson Therapy:

Prolopa[®]

4 parts L-dopa: 1 part benserazide

For the response you expect...
without the frequency
of peripheral side effects

The 4:1 ratio provides

-  Excellent clinical response in the management of Parkinsonian disability.^{1,2}
-  Significantly fewer side effects – nausea and vomiting – than a 10:1 ratio Levodopa/Carbidopa preparation during the first six months of treatment.^{1,2}
-  Patient preference over the 10:1 ratio Levodopa/Carbidopa preparation, with respect to nausea and vomiting.¹

References:

- 1) Rinne UK, Mölsä P. Neurology, 1979; 29:1584-1589.
- 2) Pakkenberg H et al, Acta Neurol. Scand 1976; 53:376-385.

Prolopa[®]

right from the start



Original Research in Medicine and Chemistry

•Reg. Trade Mark

Can. 0094

See page xvii for brief prescribing information.



**The parkinson
foundation
of canada**

Information and companionship for Parkinson patients is available from the Parkinson Foundation of Canada.
Please write or call: Suite 232, ManuLife Centre, 55 Bloor St. West, Toronto, Ontario M4W 1A6. Telephone: (416) 964-1155.

Tegretol[®]

carbamazepine

To help control
refractory generalized
tonic-clonic seizures
without excessive sedation

